Prospective, Non-interventional Observational Study to Characterize Dupilumab in the Long-term Management of Eosinophilic Esophagitis, Safety and Patient Reported Outcomes (Quality of Life) in Clinical Routine
Latest Information Update: 25 Nov 2024
Price :
$35 *
At a glance
- Drugs Dupilumab (Primary)
- Indications Eosinophilic oesophagitis
- Focus Therapeutic Use
- Acronyms ProMEAL
- Sponsors Sanofi
- 25 Nov 2024 New trial record